Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Other Accumulated Expenses (2022 - 2023)

PharmaCyte Biotech (PMCB) has disclosed Other Accumulated Expenses for 4 consecutive years, with $287310.0 as the latest value for Q3 2023.

  • Quarterly Other Accumulated Expenses fell 23.82% to $287310.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $287310.0 through Jul 2023, down 23.82% year-over-year, with the annual reading at $287310.0 for FY2023, 23.82% down from the prior year.
  • Other Accumulated Expenses for Q3 2023 was $287310.0 at PharmaCyte Biotech, roughly flat from $287310.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $467000.0 in Q1 2022, with the low at $287310.0 in Q1 2023.